There is no evidence that fenben for humans can cure cancer. It may make cancer cells lay dormant or “wake back up”, but it cannot cure them. It also has not been shown to prevent recurrent cancer.
Scientists studied the effect of fenbendazole on human non-small cell lung cancer cells. The results showed that fenbendazole interacts with the tubulin protein and causes partial alteration of the microtubule network around the nucleus. It also promotes the p53 tumor suppressor genes and interferes with glucose metabolism.
It is an anthelmintic
Fenbendazole is an anthelmintic drug that kills parasitic worms. It can also be used to treat cancerous tumors by blocking a cell’s ability to absorb glucose, which it needs to grow. It has been shown to be effective in animal studies and is being explored in human patients with advanced cancers. It has been found to stop the spread of tumors and to reduce the size of existing ones.
It was discovered by Dr. Tapas Mukhopadhyay at MD Anderson and was first tested in lab experiments in 2002. The anthelmintic’s anti-cancer properties were discovered when it was found to inhibit the growth of cancerous cells in mice. In the same study, it was also found to kill ovarian cancer cells and prevent the recurrence of cervical cancer in rats.
The anthelmintic’s potential as an anticancer agent has increased recently with the publication of Joe Tippens’ cancer cure story, which is based on his self-administration of fenbendazole. The story went viral on social media sites and caused many people to self-administer the anthelmintic. However, it is important for physicians to educate patients about the dangers of using unproven remedies.
The anthelmintic drugs in the benzimidazole family have been widely used in veterinary medicine for more than 50 years. These broad-spectrum anthelmintics have excellent antiparasitic activity against various helminth species and low toxicity in treated animals. They are effective against resistance to a large number of drugs and play a crucial role in disease control in endemic areas.
It is an anticancer agent
While there are some studies showing that fenbendazole can slow cancer cell growth in cell cultures and animals, there isn’t enough evidence to show that it can cure cancer in humans. Cancer Research UK told PolitiFact that the dog worming drug isn’t an effective cancer treatment and should be avoided. The fenbendazole craze has also been called a “fake” by scientists and has been debunked in multiple videos.
Researchers treated H4IIE rat hepatocellular carcinoma cells with fenbendazole to see how it affected their growth. They found that fenbendazole depletes glucose uptake, and inhibits proliferation of cancerous cells. The drug also causes apoptosis of cancerous cells and promotes tumor regression in vivo. It also disrupts microtubule dynamics, upregulates p53 and downregulates genes associated with several cell signaling pathways.
Another advantage of fenbendazole is that it can be used in combination with other conventional cancer treatments, such as radiation and chemotherapy. It also has a high safety margin and is well tolerated in experimental animals. Developing a new anticancer agent can be very expensive and take years, so repurposing veterinary drugs that have promising results could save time and money. However, these repurposed drugs must be tested in human clinical trials before they can be approved for use as an anticancer agent. This is why it’s important to seek the advice of a physician before trying fenbendazole.
It is a parasiticide
Fenbendazole (FZ) is a member of the benzimidazole carbamate family of anthelmintic drugs. It is effective against a wide range of parasitic worms in humans and animals. It acts by inhibiting microtubular polymerization and blocking glucose uptake in susceptible parasites, leading to reduced glycogen stores and decreased ATP formation. It also causes disruption of the mitochondrial membrane. It is particularly effective against the gastrointestinal worm Giardia lamblia.
The invention provides a compound recipe fenbendazole transdermal solution used in house pet broad-spectrum anti-parasitic medicine, which is characterized in that the formula forming component and weight mass fraction thereof are: fenbendazole 0.5%-1, Phenbendasol 0.5%-1, propylene glycol 40-70%, dimethyl sulfoxide 15%-30%, isopropanol 10%-20%, polyethylene glycol 400 (PEG400) 10%-20%, glycerol 1%-5 and azone 2%-5. The preparation method with this formula has the advantage of enhancing absorption of skins to the drug, avoiding first-pass effect of the liver and reducing gastrointestinal interaction. It also can produce constant controlled blood drug level and achieve a more clinical effect.
The government has warned cancer patients against taking dog parasiticides that were claimed to be effective in fighting tumors in a YouTube video. According to the Korea Center for Disease Control and Prevention, these products are not safe and could have dangerous side effects. In addition, they may be contaminated with toxic substances. Besides, the KCDC recommends that patients use other anticancer drugs that have been tested on human volunteers and are proven to be safe for cancer patients.
It is a fungicide
Fenbendazole and flubendazole are anthelmintics that have been shown to be effective against Ascaris, hookworms and trichuris. They act by binding to the b-tubulin subunit and inhibiting microtubule formation in intestinal cells, thereby preventing glucose uptake and starving the parasites. However, these compounds are also toxic to aquatic organisms. These effects are mainly due to their high octanol-water partition coefficients. These values far exceed those found in the environment, and can lead to toxicity of non-target aquatic organisms.
The fungicidal activities of FLU and FEN towards the algae Scenedesmus subspicatus and the daphnid Lepomis ministri and its sensitivity to light, temperature, and pH varied by more than five orders of magnitude. Both compounds also exhibited significant inhibition and delay in growth of the fungus C. albicans and C. neoformans at concentrations of greater than 1.56 mM, as well as reduced polysaccharide capsule thickness of C. gattii and Lomentospora prolificans at lower concentrations.